abrdn Income Credit Strategies ACP Pharma — D&A
Other segment segments
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — D&A?
- abrdn Income Credit Strategies (ACP) reported pharma — D&A of $2M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — D&A changed year-over-year?
- abrdn Income Credit Strategies's pharma — D&A decreased by 71.4% year-over-year, from $7M to $2M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — D&A?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — D&A has grown at a 0.0% compound annual growth rate (CAGR), from $28M to $28M.
- What does pharma — D&A mean?
- Represents the non-cash allocation of costs for tangible and intangible assets over their useful lives within the Pharma segment. This metric highlights the capital intensity of the business and the ongoing investment required to maintain operational capacity. It is a critical component for calculating cash flow metrics and understanding asset utilization.